KEMILLE BELL: Open Payments
NPI 1134438682 · ORLANDO, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,059 in 10 payments from 8 companies in 2025. Trend: 2023 $462 · 2024 $455 · 2025 $1,059
Food & beverage: $1,059
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 2 | $228 |
| Medtronic, Inc. | 2 | $158 |
| ABIOMED | 1 | $133 |
| Gilead Sciences, Inc. | 1 | $130 |
| Neurocrine BioSciences, Inc. | 1 | $125 |
| Axsome Therapeutics, Inc. | 1 | $117 |
| Teva Pharmaceuticals USA, Inc. | 1 | $100 |
| GENZYME CORPORATION | 1 | $68 |
Products named: SYMPLICITY G3, Livdelzi, INGREZZA, Wegovy, Auvelity, FABRAZYME.
Industry payments across FL — which companies pay providers there.
